As Enflonsia approaches the one-year anniversary of its approval, Merck is padding the case for a label expansion that could see the protective antibody better match Sanofi and AstraZeneca’s rival infant RSV preventive Beyfortus.
Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.
HHS has elevated a new team of health policy experts, including a former health IT exec and a Trump administration veteran.
A newly discovered bacterial duo may be the hidden cause of chronic constipation. The two microbes break down the colon’s protective mucus layer, leaving stool dry and hard — a problem traditional laxatives don’t fix. Parkinson’s patients, who often struggle with constipation years before tremors appear, have higher levels of these bacteria. Blocking the bacteria’s mucus-destroying enzyme prevente
Synthetic biology specialist Manus Bio has scored a $15 million contract from the U.S. government to create a domestic supply source for shikimic acid, a key starting material used in the production of influenza drug Tamiflu.
Myopia is skyrocketing around the world, often blamed on endless screen time — but new research suggests the real culprit may be something more subtle. Scientists at SUNY College of Optometry propose that it’s not just devices, but the combination of prolonged close-up focus and dim indoor lighting that may quietly strain the eyes. When we concentrate on nearby objects in low light, our pupils con
New FDA guidance on the use of antibiotics in food-producing animals has prompted criticism that it fails to consider the impact on human health.
He's the third leader of the public health agency since this summer.
Federal officials have missed the legal deadline to notify the public of an upcoming ACIP meeting, raising questions about whether the meeting will be postponed.
With an eye—and ear—toward spreading the perseverance and optimism ingrained in the field of science, AbbVie has launched a new podcast series touting the work of its own scientists and other experts.
As President Donald Trump attempts to convince Congress to write his Most Favored Nation drug pricing plan into law, he has received pushback from free-market conservatives. An interview with former Biden administration advisor John Barkett helps put the effort in perspective.
With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion plans that are aimed, at least in part, at abating the Trump administration’s pharmaceutical tariff threats.
As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai Immunotherapeutics.
In his report, Senator Bill Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce regulatory burdens on drugmakers.
Is there room for more Alzheimer’s antibody therapies on the market? Korsana Biosciences' investors think so.
Northwestern researchers have shown that when it comes to cancer vaccines, arrangement can be just as important as ingredients. By repositioning a small fragment of an HPV protein on a DNA-based nanovaccine, the team dramatically strengthened the immune system’s attack on HPV-driven tumors. One specific design slowed tumor growth, extended survival in animal models, and unleashed far more cancer-k
Sugary drinks may be linked to more than just physical health problems in teens. A new review of multiple studies found a consistent association between high consumption of beverages like soda, energy drinks, sweetened juices, and flavored milks and increased anxiety symptoms in adolescents.
Less than half a year after winning an inaugural green light in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is jockeying to expand its urticaria reach into a new indication where it has the potential to become the first targeted therapy.
Oncologists say there is promise in new AI tools that can guide them when choosing between two plausible treatments.
“The pharmaceutical industry is not the enemy,” writes Richard Hughes IV, who was Moderna’s VP for public policy when the Covid vaccine rolled out.